August 30, 2023 01:46 PM EDTUpdated August 31, 04:48 PM

Lilly quietly completes purchase of Padcev competitor, estimated at nearly half a billion dollars

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Eli Lilly completed its acquisition of antibody-drug conjugate biotech Emergence Therapeutics, the Indianapolis pharma company confirmed to Endpoints News Wednesday.

The buyout closed on Aug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly quietly completes purchase of Padcev competitor, estimated at nearly half a billion dollars

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Lil­ly qui­et­ly com­pletes pur­chase of Pad­cev com­peti­tor, es­ti­mat­ed at near­ly half a bil­lion dol­lars

News Reporter

Senior Reporter

Sign up to read this article for free.

Lilly quietly completes purchase of Padcev competitor, estimated at nearly half a billion dollars